

# **PROPOSITION 65 STATUS REPORT SAFE HARBOR LEVELS:**

**No Significant Risk Levels for  
Carcinogens and Maximum  
Allowable Dose Levels for  
Chemicals Causing Reproductive  
Toxicity**

**September 2003**

Reproductive and Cancer Hazard  
Assessment Section  
Office of Environmental Health Hazard  
Assessment  
California Environmental Protection  
Agency



## **TABLE OF CONTENTS**

<b>Proposition 65 Safe Harbor Levels Development.....</b>	<b>1</b>
<b>A. No Significant Risk Levels (NSRLs) Adopted in Regulation for Carcinogens.....</b>	<b>2</b>
<b>B. Maximum Allowable Dose Levels (MADLs) Adopted in Regulation for Chemicals Causing Reproductive Toxicity.....</b>	<b>8</b>
<b>C. Priority List for the Development of NSRLs for Carcinogens.....</b>	<b>9</b>
<b>D. Priority List for the Development of MADLs for Chemicals Causing Reproductive Toxicity.....</b>	<b>15</b>

## **Proposition 65 Safe Harbor Levels Development**

The Office of Environmental Health Hazard Assessment (OEHHA) of the California Environmental Protection Agency is the lead agency for the implementation of the Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65 or the Act). In that role, OEHHA has developed Proposition 65 safe harbor levels -- no significant risk levels (NSRLs) for carcinogens and maximum allowable dose levels (MADLs) for chemicals that cause reproductive toxicity. The NSRL is the daily intake level calculated to result in one excess case of cancer in an exposed population of 100,000, assuming lifetime (70-year) exposure at the level in question. The MADL is the level at which the chemical would have no observable adverse reproductive effect assuming exposure at 1,000 times that level. The NSRLs and MADLs are promulgated in Title 22, California Code of Regulations, (CCR) Sections 12705 and 12805 respectively to assist interested parties in determining whether warnings are required for exposures to listed chemicals, and whether discharges to sources of drinking water are prohibited.

Safe harbor levels may be based on risk assessments conducted outside OEHHA, as provided for in 22 CCR 12705(b), 12705(c), and 12805. In some cases, this can expedite safe harbor development. However, it should be noted that the process of review and consideration of existing risk assessments can be a lengthy one, and will depend on the complexity of the scientific information underlying the assessment, as well as on available resources.

This document provides the status of the development and adoption of intake levels calculated for all chemicals on the Proposition 65 list. In units of micrograms per day ( $\mu\text{g}/\text{day}$ ), Part A reports NSRLs adopted in regulation for carcinogens and Part B reports MADLs adopted in regulation for chemicals that cause reproductive toxicity.

Parts C and D of this document give priority levels for development of dose response assessments for chemicals that cause cancer and reproductive toxicity, respectively. Interested parties are invited to recommend changes in priority levels. OEHHA retains the right to change priorities in response to the nature and availability of scientific information, and resources available, and requests from the public and the Attorney General's office.

Parts C and D also give draft levels, some of which have been available since the early 1990's and others of which have been updated recently. OEHHA will continue to review the basis for draft numbers and update analyses as needed, before proposing or finalizing levels for formal adoption in regulation.

This status report will be updated on a regular basis.

## A. No Significant Risk Levels (NSRLs) Adopted in Regulation for Carcinogens

The table below lists NSRLs for Proposition 65 carcinogens in regulation (22 CCR §12705 and §12709). These levels are intended to provide “safe harbors” for persons subject to the Act, and do not preclude the use of alternative levels that can be demonstrated by their users as being scientifically valid.

A three-tiered procedure for development of NSRLs is currently in place. NSRLs may be based on a *de novo* dose response assessment conducted or reviewed by OEHHA (22 CCR §12705(b)), an assessment conducted by another state or federal agency (22 CCR §12705(c)), or an expedited process conducted by OEHHA (22 CCR §12705(d)). The last column of the table below indicates which of these processes was used to develop the NSRL for each chemical. NSRLs represent the daily intake level calculated to result in a cancer risk of one excess case of cancer in 100,000 individuals exposed over a 70-year lifetime.

NSRLs for chemicals in underline have been adopted since the last Status Report. As chemicals are removed from the Proposition 65 list, the regulatory process to remove the safe harbor level from regulation will be initiated.

Carcinogen	Level ( $\mu\text{g}/\text{day}$ )	22 CCR Section
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	2	12705(d)
Acetaldehyde	90 (inhalation)	12705(c)
Acetamide	10	12705(d)
2-Acetylaminofluorene	0.2	12705(d)
Acrylamide	0.2	12705(c)
Acrylonitrile	0.7	12705(b)
Actinomycin D	0.00008	12705(d)
AF-2; [2-(2-furyl)-3(5-nitro-2-furyl)acrylamide]	3	12705(d)
Aldrin	0.04	12705(b)
2-Aminoanthraquinone	20	12705(d)
o-Aminoazotoluene	0.2	12705(d)
4-Aminobiphenyl	0.03	12705(d)
3-Amino-9-ethylcarbazole hydrochloride	9	12705(d)
1-Amino-2-methylantraquinone	5	12705(d)
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	0.04	12705(d)
Amitrole	0.7	12705(d)
Aniline	100	12705(c)
o-Anisidine	5	12705(d)
o-Anisidine hydrochloride	7	12705(d)
Aramite	20	12705(d)
Arsenic	0.06 (inh) 10 (except inh)	12705(b) 12709
Asbestos	100 fibers/day (inh)	12705(b)
NSRL for fibers $\geq$ 5 micrometers (mm) long and 0.3 wide, with a length/width ratio $\geq$ 3:1 as measured by phase contrast microscopy.		
Auramine	0.8	12705(d)

Carcinogen	Level ( $\mu\text{g}/\text{day}$ )	22 CCR Section
Azaserine	0.06	12705(d)
Azathioprine	0.4	12705(d)
Azobenzene	6	12705(c)
Benzene	7	12705(b)
Benzidine	0.001	12705(b)
Benzofuran	1.1	12705(b)
Benzo[a]pyrene	0.06	12705(c)
Benzyl chloride	4	12705(c)
Benzyl violet 4B	30	12705(d)
Beryllium	0.1	12709
Beryllium oxide	0.1	12705(c)
Beryllium sulfate	0.0002	12705(c)
Bis(2-chloroethyl)ether	0.3	12705(b)
Bis(chloromethyl)ether	0.02	12705(b)
Bromodichloromethane	5	12705(c)
1,3-Butadiene	0.4	12705(c)
Butylated hydroxyanisole	4000	12705(b)
beta-Butyrolactone	0.7	12705(d)
Cadmium	0.05 (inh)	12705(b)
Captafol	5	12705(d)
Captan	300	12705(d)
Carbazole	4.1	12705(d)
Carbon tetrachloride	5	12705(b)
N-Carboxymethyl-N-nitrosourea	0.70	12705(b)
Chlorambucil	0.002	12705(d)
Chlordane	0.5	12705(c)
Chlordecone (Kepone)	0.04	12705(d)
Chlorendic acid	8	12705(d)
Chlorinated paraffins (Ave. chain length C12; approx. 60% chlorine by weight)	8	12705(d)
Chloroethane (Ethyl chloride)	150	12705(b)
Chloroform	20 (oral) 40 (inh)	12705(c) 12705(c)
Chloromethyl methyl ether (technical grade)	0.3	12705(d)
3-Chloro-2-methylpropene	5	12705(d)
4-Chloro-ortho-phenylenediamine	40	12705(d)
Chlorothalonil	200	12705(d)
p-Chloro-ortho-toluidine	3	12705(d)
p-Chloro-o-toluidine, hydrochloride	3.3	12705(d)
Chlorozotocin	0.003	12705(d)
Chromium (hexavalent)	0.001 (inh)	12705(b)
C.I. Basic Red 9 monohydrochloride	3	12705(d)
Cinnamyl anthranilate	200	12705(d)
Coke oven emissions	0.3	12705(c)
p-Cresidine	5	12705(d)
Cupferron	3	12705(d)
Cyclophosphamide (anhydrous)	1	12705(d)
Cyclophosphamide (hydrated)	1	12705(d)

Carcinogen	Level ( $\mu\text{g}/\text{day}$ )	22 CCR Section
D&C Red No. 9	100	12705(d)
Dacarbazine	0.01	12705(d)
Daminozide	40	12705(d)
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	9	12705(d)
DDT, DDE, DDD (in combination)	2	12705(b)
DDVP (Dichlorvos)	2	12705(c)
2,4-Diaminoanisole	30	12705(d)
2,4-Diaminoanisole sulfate	50	12705(d)
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	5	12705(d)
2,4-Diaminotoluene	0.2	12705(d)
Dibenz[a,h]anthracene	0.2	12705(d)
1,2-Dibromo-3-chloropropane	0.1	12705(b)
p-Dichlorobenzene	20	12705(b)
3,3'-Dichlorobenzidine	0.6	12705(b)
1,1-Dichloroethane	100	12705(d)
1,2-Dichloroethane (Ethylene dichloride)	10	12705(b)
Dichloromethane (Methylene chloride)	200 (inh) 50	12705(b) 12705(c)
Dieldrin	0.04	12705(b)
Di(2-ethylhexyl)phthalate (DEHP)	310	12705(b)
Diethylstilbestrol	0.002	12705(d)
Diglycidyl resorcinol ether (DGRE)	0.4	12705(d)
Dihydrosafrole	20	12705(d)
3,3'-Dimethoxybenzidine (o-Dianisidine)	0.15	12705(b)
3,3'-Dimethoxybenzidine dihydrochloride	0.19	12705(b)
4-Dimethylaminoazobenzene	0.2	12705(d)
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	2	12705(d)
7,12-Dimethylbenz(a)anthracene	0.003	12705(d)
3,3'-Dimethylbenzidine (o-Tolidine)	0.044	12705(b)
3,3'-Dimethylbenzidine dihydrochloride	0.059	12705(b)
Dimethylcarbamoyl chloride	0.05	12705(d)
1,2-Dimethylhydrazine	0.001	12705(d)
Dimethylvinylchloride	20	12705(d)
2,4-Dinitrotoluene	2	12705(c)
1,4-Dioxane	30	12705(b)
Direct Black 38 (technical grade)	0.09	12705(d)
Direct Blue 6 (technical grade)	0.09	12705(d)
Direct Brown 95 (technical grade)	0.1	12705(d)
Disperse Blue 1	200	12705(d)
Epichlorohydrin	9	12705(b)
Estradiol 17b	0.02	12705(d)
Ethyl-4,4'-dichlorobenzilate (Chlorobenzilate)	7	12705(d)
Ethylene dibromide	0.2 (oral) 3 (inh)	12705(b) 12705(b)
Ethylene oxide	2	12705(b)
Ethylene thiourea	20	12705(d)
Ethyleneimine	0.01	12705(d)
Folpet	200	12705(c)

Carcinogen	Level ( $\mu\text{g/day}$ )	22 CCR Section
Formaldehyde (gas)	40	12705(c)
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	0.3	12705(d)
Furmecyclox	20	12705(c)
Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole)	0.1	12705(d)
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]-imidazole)	0.5	12705(d)
Gyromitrin (Acetaldehyde methylformylhydrazone)	0.07	12705(d)
HC Blue 1	10	12705(d)
Heptachlor	0.2	12705(c)
Heptachlor epoxide	0.08	12705(c)
Hexachlorobenzene	0.4	12705(b)
Hexachlorocyclohexane		
alpha isomer	0.3	12705(c)
beta isomer	0.5	12705(c)
gamma isomer	0.6	12705(c)
technical grade	0.2	12705(b)
Hexachlorodibenzodioxin	0.0002	12705(b)
Hexachloroethane	20	12705(d)
Hydrazine	0.04	12705(c)
Hydrazine sulfate	0.2	12705(c)
Hydrazobenzene (1,2-Diphenylhydrazine)	0.8	12705(d)
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline)	0.5	12705(d)
Isobutyl nitrite	7.4	12705(d)
Lasiocarpine	0.09	12705(d)
Lead	15 (oral)	12705(b)
Lead acetate	23 (oral)	12705(b)
Lead phosphate	58 (oral)	12705(b)
Lead subacetate	41 (oral)	12705(b)
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	0.6	12705(d)
MeIQ (2-amino-3,4-dimethylimidazo-[4,5-f]quinoline)	0.46	12705(d)
MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	0.41	12705(d)
Melphalan	0.005	12705(d)
2-Methylaziridine (Propyleneimine)	0.028	12705(b)
Methyl carbamate	160	12705(d)
3-Methylcholanthrene	0.03	12705(d)
4,4'-Methylene bis(2-chloroaniline)	0.5	12705(d)
4,4'-Methylene bis(N,N-dimethyl)benzeneamine	20	12705(c)
4,4'-Methylene bis(2-methylaniline)	0.8	12705(d)
4,4'-Methylenedianiline	0.4	12705(d)
4,4'-Methylenedianiline dihydrochloride	0.6	12705(d)
Methylhydrazine	0.058 (oral) 0.090 (inhalation)	12705(b) 12705(b)
Methylhydrazine sulfate	0.18	12705(b)
Methyl methanesulfonate	7	12705(d)
2-Methyl-1-nitroanthraquinone (of uncertain purity)	0.2	12705(d)
N-Methyl-N'-nitro-N-nitrosoguanidine	0.08	12705(d)
Methylthiouracil	2	12705(d)

Carcinogen	Level ( $\mu\text{g/day}$ )	22 CCR Section
Michler's ketone	0.8	12705(d)
Mirex	0.04	12705(d)
Mitomycin C	0.00009	12705(d)
Monocrotaline	0.07	12705(d)
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)-amino]-2-oxazolidinone	0.18	12705(b)
MX (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone)	0.11	12705(b)
 Nalidixic acid	28	12705(d)
2-Naphthylamine	0.4	12705(d)
Nickel refinery dust	0.8	12705(c)
Nickel subsulfide	0.4	12705(c)
Nitrolotriacetic acid	100	12705(d)
Nitrolotriacetic acid, trisodium salt monohydrate	70	12705(d)
5-Nitroacenaphthene	6	12705(d)
5-Nitro-o-anisidine	10	12705(d)
Nitrofen (technical grade)	9	12705(d)
Nitrofurazone	0.5	12705(d)
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	0.4	12705(d)
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	0.5	12705(d)
N-Nitrosodi-n-butylamine	0.06	12705(b)
N-Nitrosodiethanolamine	0.3	12705(c)
N-Nitrosodiethylamine	0.02	12705(b)
N-Nitrosodimethylamine	0.04	12705(b)
p-Nitrosodiphenylamine	30	12705(d)
N-Nitrosodiphenylamine	80	12705(b)
N-Nitrosodi-n-propylamine	0.1	12705(b)
N-Nitroso-N-ethylurea	0.03	12705(b)
4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone	0.014	12705(d)
N-Nitrosomethylethylamine	0.03	12705(c)
N-Nitroso-N-methylurea	0.006	12705(b)
N-Nitroso-N-methylurethane	0.006	12705(d)
N-Nitrosomorpholine	0.1	12705(d)
N-Nitrosonornicotine	0.5	12705(d)
N-Nitrosopiperidine	0.07	12705(d)
N-Nitrosopyrrolidine	0.3	12705(c)
 Pentachlorophenol	40	12705(c)
Phenacetin	300	12705(d)
Phenazopyridine	4	12705(d)
Phenazopyridine hydrochloride	5	12705(d)
Phenesterin	0.005	12705(d)
Phenobarbital	2	12705(d)
Phenoxybenzamine	0.2	12705(d)
Phenoxybenzamine hydrochloride	0.3	12705(d)
<i>o</i> -Phenylenediamine	26	12705(d)
<i>o</i> -Phenylenediamine dihydrochloride	44	12705(d)
Phenyl glycidyl ether	5.0	12705(b)
Phenylhydrazine	1.0	12705(b)
Phenylhydrazine hydrochloride	1.4	12705(b)
<i>o</i> -Phenylphenate, sodium	200	12705(d)

Carcinogen	Level ( $\mu\text{g}/\text{day}$ )	22 CCR Section
Polybrominated biphenyls	0.02	12705(b)
Polychlorinated biphenyls	0.09	12705(c)
Polygeenan	1200	12705(b)
Ponceau MX	200	12705(d)
Ponceau 3R	40	12705(d)
Potassium bromate	1	12705(d)
Procarbazine	0.05	12705(d)
Procarbazine hydrochloride	0.06	12705(d)
1,3-Propane sultone	0.3	12705(d)
beta-Propiolactone	0.05	12705(d)
Propylthiouracil	0.7	12705(d)
Reserpine	0.06	12705(d)
Safrole	3	12705(d)
Sterigmatocystin	0.02	12705(d)
Streptozotocin	0.006	12705(d)
Styrene oxide	4	12705(d)
Sulfallate	4	12705(d)
Tetrachlorodibenzo-p-dioxin	0.000005	12705(b)
1,1,2,2-Tetrachloroethane	3	12705(d)
Tetrachloroethylene	14	12705(c)
Tetranitromethane	0.059	12705(b)
Thioacetamide	0.1	12705(d)
4,4'-Thiodianiline	0.05	12705(d)
Thiourea	10	12705(d)
Toluene diisocyanate	20	12705(d)
ortho-Toluidine	4	12705(d)
ortho-Toluidine hydrochloride	5	12705(d)
Toxaphene	0.6	12705(b)
Trichloroethylene	50 (oral) 80 (inh)	12705(b) 12705(b)
2,4,6-Trichlorophenol	10	12705(b)
Trimethyl phosphate	24	12705(d)
Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	0.06	12705(d)
Tris(2,3-dibromopropyl)phosphate	0.3	12705(d)
Trp-P-1 (Tryptophan-P-1)	0.03	12705(d)
Trp-P-2 (Tryptophan-P-2)	0.2	12705(d)
Urethane (Ethyl carbamate)	0.7	12705(b)
Vinyl chloride	3	12705(b)
Vinyl trichloride (1,1,2-Trichloroethane)	10	12705(d)
2,6-Xyldine	110	12705(b)

## B. Maximum Allowable Dose Levels (MADLs) Adopted in Regulation for Chemicals Causing Reproductive Toxicity

The following table is a compilation of MADLs in regulation (22 CCR §12805) for Proposition 65 chemicals that cause reproductive toxicity. These levels represent the no observable effect level (NOEL) for the chemical, divided by 1,000. NOELs are set in accordance with procedures specified in 22 CCR §12803. MADLs for chemicals in underline have been adopted since the last Status Report.

Chemical Listed as Causing Reproductive Toxicity	Level (µg/day)
Benzene	24 (oral) 49 (inhalation)
Cadmium	4.1 (oral)
<u>2,4-DB (2,4-dichlorophenoxybutyric acid)</u>	<u>910</u>
<u>m-Dinitrobenzene</u>	<u>38</u>
Ethylene oxide	20
<u>Hydramethynon</u>	<u>120 (oral)</u>
Lead	0.5
Linuron	460
<u>N-Methylpyrrolidone</u>	<u>3200 (inhalation)</u> <u>17000(dermal)</u>
Quizalofop-ethyl	590
Toluene	7000 <sup>a</sup>

<sup>a</sup> Level represents absorbed dose (rounded from 6,525 µg/day). Since 100% of ingested toluene is absorbed, oral dose is equivalent to administered dose. It is assumed that roughly 50% of the dose administered by the inhalation route is absorbed. Therefore the MADL for inhaled toluene is 13,000 µg/day (rounded from 13,050 µg/day), corresponding to an absorbed dose of 6,525 µg/day.

## C. Priority List for the Development of NSRLs for Proposition 65 Carcinogens

OEHHA has developed the following priority list, which classifies into four priorities carcinogens for which dose-response assessments have not been completed. Priority levels reflect the availability and quality of scientific data for dose-response assessments, potential for exposure, resources available to perform the assessment, commitments made in settlement of the case of AFL-CIO v. Deukmejian (Sacramento Superior Court No. 3481295) and input from the public and Attorney General's office. OEHHA anticipates proposing NSRLs for the majority of chemicals in the first priority group within the next two years, and for second priority chemicals within the next two to four years. It is unlikely that NSRLs for third and fourth priority chemicals would be released within the next three years.

Any interested party may submit recommendations to OEHHA for revising the priority assignment for any of the chemicals listed. Recommendations should be accompanied by appropriate documentation supporting the alternative priority assignment suggested. OEHHA expects changes in priorities resulting from the availability of scientific information and resources, and requests from the public and Attorney General's office.

A three-tiered procedure for development of NSRLs is currently in place. NSRLs may be based on a *de novo* dose response assessment conducted or reviewed by OEHHA (22 CCR §12705(b)), an assessment conducted by another state or federal agency (22 CCR §12705(c)), or an expedited process conducted by OEHHA (22 CCR §12705(d)). The table below lists draft NSRLs and their year of release, along with the subsection of 12705 indicating the procedure used to develop the value. OEHHA will review the basis for draft numbers and update analyses as needed, before proposing or finalizing levels for formal adoption in regulation. Chemicals in bold font have been added to the Proposition 65 list or changed in priority status since the last Status Report.

---

### 1. First Priority for NSRL Development

Acetochlor	(1992 draft NSRL: 70 µg/day [12705(c)])
Acifluorfen	(1992 draft NSRL: 20 µg/day [12705(c)])
Alachlor	(1992 draft NSRL: 9 µg/day [12705(c)])
1-Amino-2,4-dibromoanthraquinone	
Aniline hydrochloride	
Antimony oxide	
Azacitidine	
Benz[a]anthracene	(2003 draft oral NSRL: 0.033 µg/day [12705(b)])
Benzo[b]fluoranthene	(2003 draft oral NSRL: 0.096 µg/day [12705(b)])
Benzo[j]fluoranthene	(2003 draft oral NSRL: 0.11 µg/day [12705(b)])
Benzo[k]fluoranthene	
Benzotrichloride	(1993 draft oral NSRL: 0.05 µg/day [12705(c)])
2,2-Bis(bromomethyl)-1,3-propanediol	(1993 draft NSRL: 0.0002 µg/day [12705(b)])
Bromate	
Bromoform	(2003 draft NSRL: 64 µg/day [12705(b)])
Chlordimeform	(1992 draft NSRL: 0.5 µg/day [12705(c)])
p-Chloroaniline	
p-Chloroaniline hydrochloride	
Chrysene	(2003 draft oral NSRL: 0.35 µg/day [12705(b)])
C. I. Acid Red 114	
C.I. Direct Blue 15	
C.I. Direct Blue 218	

C.I. Solvent Yellow 14	
Dibenz[a,h]acridine	
Dibenz[a,j]acridine	
7H-Dibenzo[c,g]carbazole	(2003 draft oral NSRL: 0.0030 µg/day [12705(b)])
Dibenzo[a,e]pyrene	
Dibenzo[a,h]pyrene	(2003 draft oral NSRL: 0.0054 µg/day [12705(b)])
Dibenzo[a,i]pyrene	(2003 draft oral NSRL: 0.0050 µg/day [12705(b)])
Dibenzo[a,l]pyrene	
3,3'-Dichlorobenzidine dihydrochloride	
1,2-Dichloropropane	
1,3-Dichloropropene	(1993 draft oral NSRL: 4 µg/day [12705(b)]) (1993 draft inhalation NSRL: 20 µg/day [12705(c)])
Diepoxybutane	
Diethyl sulfate	(1993 draft NSRL: 0.7 µg/day [12705(b)])
Dimethyl sulfate	(1993 draft NSRL: 0.05 µg/day [12705(b)])
1,1-Dimethylhydrazine (UDMH)	(1992 draft NSRL: 0.3 µg/day [12705(b)])
1,6-Dinitropyrene	(1993 draft NSRL: 0.02 µg/day [12705(b)])
1,8-Dinitropyrene	(1993 draft NSRL: 0.01 µg/day [12705(b)])
2,6-Dinitrotoluene	
Estragole	
Ethinylestradiol	
Furan	
Glycidol	(1992 draft NSRL: 0.4 µg/day [12705(b)])
Griseofulvin	(1992 draft NSRL: 50 µg/day [12705(b)])
Hexamethylphosphoramide	(1992 draft NSRL: 0.01 µg/day [12705(b)])
Indeno[1,2,3-cd]pyrene	
Isoprene	
Lactofen	(1992 draft NSRL: 4 µg/day [12705(c)])
5-Methylchrysene	(2003 draft oral NSRL: 0.0084 µg/day [12705(b)])
Methyleugenol	
Methylmercury compounds*	
N-Methylolacrylamide	(1992 draft NSRL: 2 µg/day [12705(b)])
Metronidazole	(1992 draft NSRL: 4 µg/day [12705(b)])
Nafenopin	
Naphthalene	
Nickel carbonyl	
o-Nitroanisole	
Nitrobenzene	
4-Nitrobiphenyl	
6-Nitrochrysene	(1993 draft NSRL: 0.002 µg/day [12705(b)])
2-Nitrofluorene	(1993 draft NSRL: 0.09 µg/day [12705(b)])
2-Nitropropane	(1993 draft inhalation NSRL: 30 µg/day [12705(b)])
1-Nitropyrene	(1993 draft NSRL: 0.6 µg/day [12705(b)])
4-Nitropyrene	(1993 draft NSRL: 0.03 µg/day [12705(b)])
N-Nitrosomethylvinylamine	(1993 draft NSRL: 0.004 µg/day [12705(b)])
N-Nitrososarcosine	(1993 draft NSRL: 5 µg/day [12705(b)])
Ochratoxin A	(1992 draft NSRL: 0.03 µg/day [12705(b)])
Oxazepam	
<i>o</i> -Phenylphenol	
PhiP	
<b>Progesterone</b>	
Pronamide	

\* For explanation of priority levels see discussion above.

Pyridine	
Selenium sulfide	
1,2,3-Trichloropropane	
Tris(2-chloroethyl)phosphate	
Vinyl bromide	(1992 draft oral NSRL: 1 µg/day [12705(b)])
	(1992 draft inhalation NSRL: 4 µg/day [12705(b)])
4-Vinylcyclohexene	

It is anticipated that changes to NSRLs currently in regulation will be proposed or adopted during the next year for the following chemicals:

Acrylamide	
Benzene	(2003 draft oral NSRL: 6.4 µg/day [12705 (b)])
	(2003 draft inhalation NSRL: 13 µg/day [12705 (b)])
Chromium (VI)	
Ethylene thiourea	
<i>o</i> -Phenylphenate, sodium	
Pentachlorophenol	
Safrole	
Tetrachloroethylene	

## 2. Second Priority for NSRL Development

Aflatoxins	(1992 draft NSRL: 0.02 µg/day [12705(b)])
<i>p</i> -Aminoazobenzene	
Bis(2-chloro-1-methylethyl)ether, technical grade	
Bromoethane	
Cacodylic acid	
<b>Catechol</b>	
Ceramic fibers (airborne particles of respirable size)	
1-Chloro-4-nitrobenzene	
Chloroprene	
5-Chloro- <i>o</i> -toluidine and its strong acid salts	
Cobalt metal powder	
Cobalt [II] oxide	
Cobalt sulfate heptahydrate	
Diaminotoluene (mixed)	
2,3-Dibromo-1-propanol	
Dichloroacetic acid	
1,4-Dichloro-2-butene	
Diesel engine exhaust	
Di- <i>n</i> -propyl isocinchomeronate (MGK Repellent 326)	
Diuron	
Ethoprop	
Fenoxy carb	
Indium phosphide	
Iprodione	
Isoxaflutole	
Isosafrole	
Metham sodium	
Methyl iodide	
1-Naphthylamine	
Nickel and certain nickel compounds	
Nitromethane	

*o*-Nitrotoluene  
Oxadiazon  
Oxythioquinox  
Polychlorinated dibenzo-p-dioxins  
Primidone  
Propachlor  
Quinoline and its strong acid salts  
Radionuclides  
Salicylazosulfapyridine  
Silica, crystalline (airborne particles of respirable size)  
Testosterone and its esters  
p-a,a,a-Tetrachlorotoluene  
Tetrafluoroethylene  
2,4,5-Trimethylaniline and its strong acid salts  
Triphenyltin hydroxide  
Trypan blue (commercial grade)  
4-Vinyl-1-cyclohexene diepoxide

3. Third Priority for NSRL Development

Adriamycin (Doxorubicin hydrochloride)  
Benzidine-based dyes  
N,N-Bis(2-chloroethyl)-2-naphthylamine  
Bischloroethyl nitrosourea (BCNU) (Carmustine)  
1,4-Butanediol dimethanesulfonate (Busulfan)  
Carbon black (airborne, unbound particles of respirable size)  
Chloramphenicol  
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)  
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea  
Chlorotrianisene  
Ciclosporin (Cyclosporin A; Cyclosporine)  
Cidofovir  
Cisplatin  
Clofibrate  
Daunomycin  
N,N'-Diacetylbenzidine  
3,3'-Dichloro-4,4'-diaminodiphenyl ether  
Dienestrol  
1,2-Diethylhydrazine  
Diisopropyl sulfate  
2,4-/2,6-Dinitrotoluene mixture  
Diphenylhydantoin (Phenytoin)  
Diphenylhydantoin (Phenytoin), sodium salt  
Estrone  
Estropipate  
Ethyl acrylate  
Furazolidone  
Fusarin C  
Ganciclovir sodium  
Gasoline engine exhaust (condensates/extracts)  
Gemfibrozil  
Glasswool fibers (airborne particles of respirable size)  
Glycidaldehyde  
Mancozeb

Maneb  
Medroxyprogesterone acetate  
Merphalan  
Mestranol  
Metiram  
Mustard Gas  
Niridazole  
Nitrogen mustard (Mechlorethamine)  
Nitrogen mustard hydrochloride (Mechlorethamine HC1)  
Norethisterone (Norethindrone)  
Oxymetholone  
Panfuran S  
Polychlorinated dibenzofurans  
Procymidone  
Propargite  
Propylene oxide (1991 draft oral NSRL: 3 µg/day [12705(c)])  
(1991 draft inhalation NSRL: 60 µg/day [12705(c)])  
Spironolactone  
Stanozolol  
Strong inorganic acid mists containing sulfuric acid  
Tamoxifen and its salts  
Terrazole  
Thiodicarb  
Thorium dioxide  
Treosulfan  
Trichlormethine (Trimustine hydrochloride)  
Uracil mustard  
Vinclozolin  
Vinyl fluoride  
Zileuton

4. Fourth Priority for NSRL Development

Alcoholic beverages  
2-Aminofluorene  
4-Amino-2-nitrophenol  
Analgesic mixtures containing phenacetin  
Betel quid with tobacco  
Bitumens, extracts of steam-refined  
Bracken fern  
Caffeic acid  
Carbon-black extracts  
Certain combined chemotherapy for lymphomas  
Citrus Red No. 2  
Conjugated estrogens  
Creosotes  
Cycasin  
Cytembena  
D&C Orange No. 17  
D&C Red No. 8  
D&C Red No. 19  
3,7-Dinitrofluoranthene  
3,9-Dinitrofluoranthene  
Erionite

Ethyl methanesulfonate  
Iron dextran complex  
Lynestrenol  
8-Methoxypsoralen with ultraviolet A therapy  
5-Methoxypsoralen with ultraviolet A therapy  
Methylazoxymethanol  
Methylazoxymethanol acetate  
Nitrogen mustard N-oxide  
Nitrogen mustard N-oxide hydrochloride  
3-(N-Nitrosomethylamino)propionitrile  
Norethynodrel  
Oil Orange SS  
Oral contraceptives, combined  
Oral contraceptives, sequential  
Palygorskite fibers  
Phenolphthalein  
Residual (heavy) fuel oils  
Shale-oils  
Soots, tars, and mineral oils  
Talc containing asbestos fibers  
Tobacco, oral use of smokeless products  
Tobacco smoke  
Tris(aziridinyl)-para-benzoquinone (Triaziquone)  
Unleaded gasoline (wholly vaporized)

## **D. Priority List for the Development of MADLs for Chemicals Causing Reproductive Toxicity**

OEHHA has developed the following priority list, which divides chemicals causing reproductive toxicity for which dose-response assessments have not been completed into three priorities. Priority levels reflect the availability and quality of scientific data for dose-response assessments, potential for exposure, resources available to perform the assessment, and input from the public and the Attorney General's office. OEHHA anticipates proposing MADLs for the majority of chemicals in the first priority group within the next two years, and for several chemicals in the second priority within the next two to four years. It is unlikely that MADLs for chemicals in the third priority group would be released within the next three years.

Any interested party may submit recommendations to OEHHA on revising the priority assignment for any of the chemicals listed. Recommendations should be accompanied by appropriate documentation supporting the alternative priority assignment suggested. OEHHA expects changes in priorities resulting from the availability of scientific information and resources and requests from the public and Attorney General's office.

Also given below are draft levels available and year of release. OEHHA will review the basis for draft numbers and update analyses as needed, before proposing or finalizing levels for formal adoption in regulation. Chemicals in bold font have been added to the Proposition 65 list or changed in priority status since the last Status Report.

### **1. First Priority for MADL Development**

Arsenic (inorganic oxides)	(2003 draft oral MADL: 0.10 µg/day)
Carbon disulfide	(1994 draft oral MADL: 600 µg/day)
1,2-Dibromo-3-chloropropane (DBCP)	(1994 draft inhalation MADL: 1000 µg/day)
Ethylene glycol monoethyl ether	(1994 draft MADL: 5 µg/day)
Ethylene glycol monomethyl ether	
Ethylene glycol monoethyl ether acetate	
Ethylene glycol monomethyl ether acetate	
Mercury and mercury compounds*	
Metham sodium	
Methyl bromide as a structural fumigant	(1994 draft MADL: 1000 µg/day)
Methyl mercury*	(1994 draft MADL: 0.3 µg/day)
Nicotine	
Thiophanate-methyl	
Triphenyl tin hydroxide	
Vinclozolin	

### **2. Second Priority for MADL Development**

Amitraz
Bromacil lithium salt
Bromoxynil
Bromoxynil octanoate
Chinomethionat (Oxythioquinox)
Chlorsulfuron
Cocaine

---

\* For explanation of priority levels see discussion above.

Cycloate  
Dichlorophene  
Diclofop methyl  
Disodium cyanodithiomidocarbonate  
Ethyl dipropylthiocarbamate  
Ethylene thiourea  
Fenoxyprop ethyl  
Fluazifop butyl  
Fluvalinate  
Methazole  
Metiram  
Myclobutanol  
Nabam  
Nitrapyrin  
Oxadiazon  
Oxydemeton methyl  
Potassium dimethyldithiocarbamate  
Propargite  
Resmethrin  
Sodium dimethyldithiocarbamate  
Sodium fluoroacetate  
Terbacil  
2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD)  
Triadimefon  
Tributyltin methacrylate  
Triforine

3. Third Priority for MADL Development

Acetazolamide  
Acetohydroxamic acid  
Actinomycin D  
All-trans retinoic acid  
Alprazolam  
Altretamine  
Amantadine hydrochloride  
Amikacin sulfate  
Aminoglutethimide  
Aminoglycosides  
Aminopterin  
Amiodarone hydrochloride  
Amoxapine  
Anabolic steroids  
Angiotensin converting enzyme (ACE) inhibitors  
Anisindione  
Aspirin  
Atenolol  
Auranofin  
Azathioprine  
Barbiturates  
Beclomethasone dipropionate  
Benomyl  
Benzphetamine hydrochloride  
Benzodiazepines

Bischloroethyl nitrosourea (BCNU) (Carmustine)  
Butabarbital sodium  
1,4-Butanediol dimethanesulfonate (Busulfan)  
Carbamazepine  
Carbon monoxide  
Carboplatin  
Chenodiol  
Chlorambucil  
Chlorcyclizine hydrochloride  
Chlordecone (Kepone)  
Chlordiazepoxide  
Chlordiazepoxide hydrochloride  
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)  
Cidofovir  
Cladribine  
Clarithromycin  
Clobetasol propionate  
Clomiphene citrate  
Clorazepate dipotassium  
Codeine phosphate  
Colchicine  
Conjugated estrogens  
Cyanazine  
Cycloheximide  
Cyclophosphamide (anhydrous)  
Cyclophosphamide (hydrated)  
Cyhexatin  
Cytarabine  
Dacarbazine  
Danazol  
Daunorubicin hydrochloride  
*o,p'*-DDT  
*p,p'*-DDT  
Demeclocycline hydrochloride (internal use)  
Diazepam  
Diazoxide  
Dichlophenamide  
Dicumarol  
Diethylstilbestrol (DES)  
Diflunisal  
Dihydroergotamine mesylate  
Diltiazem hydrochloride  
*o*-Dinitrobenzene  
*p*-Dinitrobenzene  
2,4-Dinitrotoluene  
2,6-Dinitrotoluene  
Dinitrotoluene (technical grade)  
Dinocap  
Dinoseb  
Diphenylhydantoin (Phenytoin)  
Doxorubicin hydrochloride  
Doxycycline (internal use)  
Doxycycline calcium (internal use)  
Doxycycline hyclate (internal use)

Doxycycline monohydrate (internal use)  
Endrin  
Epichlorohydrin  
Ergotamine tartrate  
Estropipate  
Ethionamide  
Ethyl alcohol in alcoholic beverages  
Ethylene dibromide  
Etodolac  
Etoposide  
Etretinate  
Filgrastim  
Flunisolide  
Fluorouracil  
Fluoxymesterone  
Flurazepam hydrochloride  
Flurbiprofen  
Flutamide  
Fluticasone propionate  
Ganciclovir sodium  
Gemfibrozil  
Goserelin acetate  
Halazepam  
Halobetasol propionate  
Haloperidol  
Halothane  
Heptachlor  
Hexachlorobenzene  
Hexamethylphosphoramide  
Histrelin acetate  
Hydroxyurea  
Idarubicin hydrochloride  
Ifosfamide  
Iodine-131  
Isotretinoin  
Leuprolide acetate  
Levodopa  
Levonorgestrel implants  
Lithium carbonate  
Lithium citrate  
Lorazepam  
Lovastatin  
Mebendazole  
Medroxyprogesterone acetate  
Megestrol acetate  
Melphalan  
Menotropins  
Meprobamate  
Mercaptopurine  
Methacycline hydrochloride  
Methimazole  
Methotrexate  
Methotrexate sodium  
Methyl chloride

Methyltestosterone  
Midazolam hydrochloride  
Minocycline hydrochloride (internal use)  
Misoprostol  
Mitoxantrone hydrochloride  
Nafarelin acetate  
Neomycin sulfate (internal use)  
Netilmicin sulfate  
Nickel carbonyl  
Nifedipine  
Nimodipine  
Nitrofurantoin  
Nitrogen mustard (Mechlorethamine)  
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)  
Norethisterone (Norethindrone)  
Norethisterone acetate (Norethindrone acetate)  
Norethisterone (Norethindrone)/Ethinyl estradiol  
Norethisterone (Norethindrone)/Mestranol  
Norgestrel  
Oxazepam  
Oxymetholone  
Oxytetracycline (internal use)  
Oxytetracycline hydrochloride (internal use)  
Paclitaxel  
Paramethadione  
Penicillamine  
Pentobarbital sodium  
Pentostatin  
Phenacemide  
Phenprocoumon  
Pimozone  
Pipobroman  
Plicamycin  
Polybrominated biphenyls  
Polychlorinated biphenyls  
Pravastatin sodium  
Prednisolone sodium phosphate  
Procarbazine hydrochloride  
Propylthiouracil  
Pyrimethamine  
Quazepam  
Retinol/retinyl esters, when in daily dosages in  
excess of 10,000 IU, or 3,000 retinol equivalents.  
Ribavirin  
Rifampin  
Secobarbital sodium  
Sermorelin acetate  
Streptomycin sulfate  
Streptozocin (streptozotocin)  
Sulfasalazine  
Sulindac  
Tamoxifen citrate  
Temazepam  
Teniposide

Testosterone cypionate  
Testosterone enanthate  
Tetracycline (internal use)  
Tetracyclines (internal use)  
Tetracycline hydrochloride (internal use)  
Thalidomide  
Thioguanine  
Tobacco smoke (primary)  
Tobramycin sulfate  
Triazolam  
Trentine hydrochloride  
Trilostane  
Trimethadione  
Trimetrexate glucuronate  
Uracil mustard  
Urethane  
Urofollitropin  
Valproate (Valproic acid)  
Vinblastine sulfate  
Vincristine sulfate  
Warfarin  
Zileuton